ArticleScientific reports2025
Role of Notch gene receptors as prognostic biomarkers in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of colorectal cancer (CRC) is increasing across the world, especially in younger age groups and the Indian subcontinent. Dysregulation in Notch pathway genes and their Single Nucleotide Polymorphism (SNPs) can potentially lead to aberrant signaling and contribute to CRC development. We investigated SNPs of Notch1 (rs3124591), Notch2 (rs10910779), Notch3 (rs1043994), and Notch4 (rs367398) in CRC (n = 103) and Controls (n = 103) along with their protein expression in the cases. The SNPs were detected by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism method followed by Sanger sequencing. The protein expression was determined by the western blot technique. SPSS was used to analyze the correlations of the molecular findings with clinicopathological features and survival. The frequency of CT genotype in Notch1 was significantly lower in CRC patients compared to healthy controls (40.77% vs 62.14%; p = 0.009) and was associated with increased depth of invasion (p = 0.03). Notch3 polymorphism A > G showed significant association with the advanced TNM stage (p = 0.013). Interestingly, AG and GG genotype in Notch3 was significantly associated with increased protein expression (p = 0.047). The patients carrying the 'G' allele in Notch3 had an increased risk of having CRC (OR = 1.697, CI 95%: 1.001-2.873, p = 0.049) and a lower survival rate (p > 0.05). Notch4 polymorphism showed an association with tumor grade (p = 0.03). The genotypes CT and TT had lower survival rates than the CC genotype (p = 0.08). Notch receptor polymorphism, especially Notch3, is associated with increased protein expression and a higher risk of having CRC. Furthermore, poor survival in patients with Notch3 and Notch4 polymorphism suggests their potential as prognostic biomarker in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.